ArticleJournal of biochemical and molecular toxicology2026
Differential and Combined Therapeutic Effects of Mesenchymal Stem Cells and Glutathione on Methotrexate-Induced Mucositis.
Article in Journal of biochemical and molecular toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Differential and Combined Therapeutic Effects of Mesenchymal Stem Cells and Glutathione on Methotrexate-Induced Mucositis.Journal of biochemical and molecular toxicology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Methotrexate (MTX) is commonly used in chemotherapy but induces severe side effects, such as intestinal mucositis, which is characterized by oxidative stress, inflammation, and epithelial cell death. Mesenchymal stem cells (MSCs) and glutathione (GSH) are potential therapeutic agents that could alleviate these effects. In this study, 30 adult female Wistar-Albino rats were assigned to five groups (n = 6) and received either an intraperitoneal dose of MTX (45 mg/kg) followed by treatments of MSCs, GSH, or a combination. MSCs were isolated and confirmed for multipotent differentiation capabilities. The effects of the treatments were assessed through histopathological analysis, immunohistochemistry, biochemical analyses, and gene expression using RT-qPCR. The MTX group showed significant mucosal damage, including villus atrophy, epithelial shedding, and increased fibrosis. However, treatment groups demonstrated partial preservation of villus architecture and reduced histopathological damage compared with the MTX group. MTX administration also markedly increased inflammatory and apoptotic markers, including TNF-α, IL-1β, and caspase-3, whereas these elevations were reduced to varying extents following MSC and/or GSH treatment. Additionally, MTX elevated malondialdehyde (MDA) levels and decreased antioxidant enzyme activities, MSC and/or GSH treatments attenuated oxidative stress and improved antioxidant parameters. In conclusion, the combination of MSCs and GSH treatment attenuated MTX-induced intestinal injury through reduction of oxidative stress, inflammation and apoptosis and enhancement of mucosal recovery. The findings suggest that MSC and GSH may exert complementary protective effects against MTX-induced intestinal toxicity; however, definitive superiority of the combined treatment over monotherapies was not consistently supported by the statistical analyses. However, further studies with larger sample sizes and mechanistic studies are needed to elucidate the underlying interactions and to confirm translational applicability.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.